BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 30871576)

  • 1. Design and analysis of stably integrated reporters for inducible transgene expression in human T cells and CAR NK-cell lines.
    Kulemzin SV; Matvienko DA; Sabirov AH; Sokratyan AM; Chernikova DS; Belovezhets TN; Chikaev AN; Taranin AV; Gorchakov AA
    BMC Med Genomics; 2019 Mar; 12(Suppl 2):44. PubMed ID: 30871576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of an NFκB-Driven Alpharetroviral "All-in-One" Vector Construct as a Potent Tool for CAR NK Cell Therapy.
    Rudek LS; Zimmermann K; Galla M; Meyer J; Kuehle J; Stamopoulou A; Brand D; Sandalcioglu IE; Neyazi B; Moritz T; Rossig C; Altvater B; Falk CS; Abken H; Morgan MA; Schambach A
    Front Immunol; 2021; 12():751138. PubMed ID: 34804035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
    Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
    Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
    Caforio M; Sorino C; Caruana I; Weber G; Camera A; Cifaldi L; De Angelis B; Del Bufalo F; Vitale A; Goffredo BM; De Vito R; Fruci D; Quintarelli C; Fanciulli M; Locatelli F; Folgiero V
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
    Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
    Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
    J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors.
    Oei VYS; Siernicka M; Graczyk-Jarzynka A; Hoel HJ; Yang W; Palacios D; Almåsbak H; Bajor M; Clement D; Brandt L; Önfelt B; Goodridge J; Winiarska M; Zagozdzon R; Olweus J; Kyte JA; Malmberg KJ
    Cancer Immunol Res; 2018 Apr; 6(4):467-480. PubMed ID: 29459477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.
    Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S
    Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional regulation of the gene encoding the human C-type lectin leukocyte receptor AIM/CD69 and functional characterization of its tumor necrosis factor-alpha-responsive elements.
    López-Cabrera M; Muñoz E; Blázquez MV; Ursa MA; Santis AG; Sánchez-Madrid F
    J Biol Chem; 1995 Sep; 270(37):21545-51. PubMed ID: 7665567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.
    Xu Y; Liu Q; Zhong M; Wang Z; Chen Z; Zhang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
    J Hematol Oncol; 2019 May; 12(1):49. PubMed ID: 31097020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-efficient lentiviral vector-mediated gene transfer into primary human NK cells.
    Micucci F; Zingoni A; Piccoli M; Frati L; Santoni A; Galandrini R
    Exp Hematol; 2006 Oct; 34(10):1344-52. PubMed ID: 16982327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.
    Li Y; Hermanson DL; Moriarity BS; Kaufman DS
    Cell Stem Cell; 2018 Aug; 23(2):181-192.e5. PubMed ID: 30082067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis and optimization of protocols for producing recombinant lentivirus carrying the anti-Her2 chimeric antigen receptor gene.
    Yuan W; Chen J; Cao Y; Yang L; Shen L; Bian Q; Bin S; Li P; Cao J; Fang H; Gu H; Li H
    J Gene Med; 2018 Jul; 20(7-8):e3027. PubMed ID: 29851200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
    Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
    Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering NK-CAR.19 cells with the IL-15/IL-15Rα complex improved proliferation and anti-tumor effect
    Silvestre RN; Eitler J; de Azevedo JTC; Tirapelle MC; Fantacini DMC; de Souza LEB; Swiech K; Covas DT; Calado RT; Montero PO; Malmegrim KCR; Figueiredo ML; Tonn T; Picanço-Castro V
    Front Immunol; 2023; 14():1226518. PubMed ID: 37818365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway.
    Tomkowicz B; Walsh E; Cotty A; Verona R; Sabins N; Kaplan F; Santulli-Marotto S; Chin CN; Mooney J; Lingham RB; Naso M; McCabe T
    PLoS One; 2015; 10(10):e0140694. PubMed ID: 26492563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
    Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
    Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages.
    Zhang P; Zhao S; Wu C; Li J; Li Z; Wen C; Hu S; An G; Meng H; Zhang X; Yang L
    Immunotherapy; 2018 Aug; 10(11):935-949. PubMed ID: 30149762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized Production of Lentiviral Vectors for CAR-T Cell.
    Moço PD; de Abreu Neto MS; Fantacini DMC; Picanço-Castro V
    Methods Mol Biol; 2020; 2086():69-76. PubMed ID: 31707668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.